Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies

Kozlovskaya, L.I.; Piniaeva, A.N.; Ignatyev, G.M.; Gordeychuk, I.V.; Volok, V.P.; Rogova, Y.V.; Shishova, A.A.; Kovpak, A.A.; Ivin, Y.Y.; Antonova, L.P.; Mefyod, K.M.; Prokosheva, L.S.; Sibirkina, A.S.; Tarasova, Y.Y.; Bayurova, E.O.; Gancharova, O.S.; Illarionova, V.V.; Glukhov, G.S.; Sokolova, O.S.; Shaitan, K.V.; Moysenovich, A.M.; Gulyaev, S.A.; Gulyaeva, T.V.; Moroz, A.V.; Gmyl, L.V.; Ipatova, E.G.; Kirpichnikov, M.P.; Egorov, A.M.; Siniugina, A.A.; Ishmukhametov, A.A.

Авторы: Kozlovskaya Liubov I., Piniaeva Anastasia N., Ignatyev Georgy M., Gordeychuk Ilya V., Volok Viktor P., Rogova Yulia V., Shishova Anna A., Kovpak Anastasia A., Ivin Yury Yu, Antonova Liliya P., Mefyod Kirill M., Prokosheva Lyubov S., Sibirkina Anna S., Tarasova Yuliya Yu, Bayurova Ekaterina O., Gancharova Olga S., Illarionova Victoria V., Glukhov Grigory S., Sokolova Olga S., Shaitan Konstantin V., Moysenovich Anastasia M., Gulyaev Stanislav A., Gulyaeva Tatiana V., Moroz Andrey V., Gmyl Larissa V., Ipatova Elena G., Kirpichnikov Mikhail P., Egorov Alexey M., Siniugina Aleksandra A., Ishmukhametov Aydar A.
Журнал: Emerging Microbes & Infections
Том: 10
Номер: 1
Год издания: 2021
Издательство: TAYLOR & FRANCIS LTD
Местоположение издательства: 4 PARK SQUARE, MILTON PARK, ABINGDON,ENGLAND, OXON, OX14 4RN
DOI: 10.1080/22221751.2021.1971569
Аннотация: The unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality papers describing clinical trials of different vaccine products, basic detailed data on general toxicity, reproductive toxicity, immunogenicity, protective efficacy and durability of immune response in animal models are scarce. Here, we developed a β-propiolactone-inactivated whole virion vaccine CoviVac and assessed its safety, protective efficacy, immunogenicity and stability of the immune response in rodents and non-human primates. The vaccine showed no signs of acute/chronic, reproductive, embryo-, and fetotoxicity, or teratogenic effects, as well as no allergenic properties in studied animal species. The vaccine induced stable and robust humoral immune response both in form of specific anti-SARS-CoV-2 IgG and NAbs in mice, Syrian hamsters, and common marmosets. The NAb levels did not decrease significantly over the course of one year. The course of two immunizations protected Syrian hamsters from severe pneumonia upon intranasal challenge with the live virus. Robustness of the manufacturing process was demonstrated as well. These data encouraged further evaluation of CoviVac in clinical trials.
Добавил в систему: Рамонова Алла Аликовна

	ИСТИНА	Войти в систему Регистрация
	ИСТИНА ИНХС РАН
	Главная Поиск Статистика О проекте Помощь

ИСТИНА

ИСТИНА ИНХС РАН

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studiesстатья Исследовательская статья

Прикрепленные файлы